🟢 Veraxa Biotech is trading 7.94% up in pre-market with no clear catalyst identified

Veraxa Biotech is trading at $1.36, up 7.94%, in pre-market, with no clear company-specific catalyst identified.

• The latest company release, dated October 7, covered FDA-aligned research methods.
• The investor-relations page lists the World ADC Congress beginning October 12, but no evidence links it to the move.
• Major U.S. indices were modestly higher, but none exceeded the 0.5% threshold; available information does not establish a reason for the move.